References
- Krauss GL. Perampanel: a selective AMPA antagonist for treating seizures: perampanel: a selective AMPA antagonist. Epilepsy Curr. 2013;13(6):269–272.
- Hoppner AC, Fauser S, Kerling F. Clinical course of intoxication with the new anticonvulsant drug perampanel. Epileptic Disord. 2013;15(3):362–364.
- Kim S, Kim TE, Kim D, et al. Prolonged stupor in perampanel overdose and pharmacokinetic considerations. J Epilepsy Res. 2018;8(2):87–89.
- Parsons G, Bailey J, Bailey F, et al. Prolonged unconsciousness in perampanel overdose. BMJ Case Rep. 2019;12(11):e232517.
- Wu CC, McShane M, Huttlin EA, et al. Severe aggression after perampanel overdose: case report. Psychosomatics. 2019;60(3):321–324.
- Tabuchi H, Shiba S, Yasuda S, et al. Pharmacokinetics of perampanel in healthy Korean, white, and Japanese adult subjects. Clin Pharmacol Drug Dev. 2018;7(6):613–620.
- Qozi M, Cantrell FL. Pediatric perampanel poisoning. Am J Emerg Med. 2020;38(7):1545.
- Gaudio E, Gienapp AJ, Wheless J. Perampanel pharmacokinetics in children: correlation of dose with serum concentrations. J Child Neurol. 2019;34(8):427–431.
- Gidal BE, Ferry J, Majid O, et al. Concentration–effect relationships with perampanel in patients with pharmacoresistant partial‐onset seizures. Epilepsia. 2013;54(8):1490–1497.
- Hibi S, Ueno K, Nagato S, et al. Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem. 2012;55(23):10584–10600.
- Li K, Lasoff DR, Smollin CG, et al. Perampanel overdose causing a prolonged coma. Clin Toxicol. 2018;56(7):677–678.
- Steinhoff BJ, Hübers E, Kurth C, et al. Plasma concentration and clinical effects of perampanel-The Kork experience. Seizure. 2019;67:18–22.